Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival

Table 3 Prevalence of comorbidities according to the Charlson Comorbidity index

CCI^a	condition	n	%	p-value°	HR (95% CI)
1	myocardial infarction, coronary artery disease	36	13,5	0.38	0.85 (0.58–1.23)
	congestive heart failure	15	5,6	0.62	0.87 (0.51–1.50)
	peripheral vascular disease	55	20,7	0.81	0.96 (0.71–1.31)
	cerebrovascular disease	13	4,9	0.58	0.85 (0.48–1.52)
	dementia	0	0
	chronic pulmonary disease	21	7,9	0.046	0.61 (0.38–0.99)
	connective tissue disorder	2	0,8	0.93	0.94 (0.23–3.78)
	peptic ulcer disease	2	0,8	0.006	7.40 (1.80–30.50)
	mild liver disease	10	3,8	0.26	1.44 (0.76–2.72)
	diabetes without complications	42	15,8	0.94	0.99 (0.70–1.40)
2	diabetes with end-organ damage	17	6,4	0.74	0.92 (0.55–1.52)
	hemiplegia	1	0,4	0.70	1.48 (0.21–10.61)
	moderate/severe renal disease	12	4,5	0.005	2.3 (1.29–4.13)
	any tumor without metastases (incl. Leukemia, lymphoma)	34	12,8	0.89	1.03 (0.71–1.50)
3	moderate/severe liver disease	3	1,1	0.33	1.77 (0.57–5.55)
6	metastatic solid tumor (mCRC excluded)	0	0
6	AIDS	0	0
8	AIDS and any tumor	0	0

^aage adjusted index CACI adds 1 point for each decade after 40 years
°statistics for overall survival according to univariate Cox regression, variables with univariate p < 0.1 are processed in Table 4

ISSN: 1471-2407